Abbott Laboratories Settles Infant Formula Lawsuits for $670 Million

Key Facts

In a move reflecting efforts to mitigate escalating legal and financial risks, Abbott Laboratories has agreed to pay $670 million to settle lawsuits alleging its specialized formula for premature infants causes serious intestinal disease. According to reports, this settlement follows a $495 million judgment upheld against the company earlier this year. Despite this agreement, Abbott continues to face significant legal pressure with over 1,700 additional lawsuits remaining active across the United States regarding similar claims.

This substantial settlement highlights the ongoing challenges the company faces within its pediatric healthcare segment. Per market data, these financial liabilities arrive as investors attempt to gauge the long-term impact of litigation on the company's balance sheet. Analyst assessments suggest a mixed sentiment, as the settlement provides some clarity on legal liabilities but represents a significant cash outflow amid a high volume of unresolved cases.

Regarding stock performance, ABT shares stood at $114.14 (at close August 20, 2026), having traded between a day high of $115.23 and a low of $113.99. Traders are currently monitoring support and resistance levels near these marks, especially as the upcoming economic calendar shows no immediate direct catalysts for the company, leaving the focus on how these legal settlements will influence investor confidence in the near term.